Objective
Metastasis is the primary reason for cancer death, and metastatic spread drastically worsens the prognosis of cancer patients. As cell migration is the biological process underlying the spread of cancer cells, better understanding of it is crucial for the development of novel therapies in reducing cancer invasion and increasing patient survival. Yet, little has been accomplished in terms of the development of anti-metastasis drugs. MRCKa is an effector of Rho GTPase, and molecular studies have suggested it to play important roles in cancer cell migration. However, the potential of targeting MRCKa in metastasis has not been validated due to the lack of in vivo evidence and specific inhibitors. Hence, this project aims to validate MRCKa as an important drug target for the treatment of metastatic cancers. The first objective aims to investigate
the role of MRCKa in cancer development and metastasis by utilizing a breast cancer model on MRCKa knockout mice. Secondly, MRCKa was reported to influence cell migration by multiple mechanisms, including promoting cell contraction, reducing actin turnover, and filopodia formation. To better define the molecular signaling of MRCKa during metastasis, the importance of these effector pathways in cancer cell migration will be investigated. Specifically, MRCKa knockout breast cancer cell line derivatives will first be generated, and their ability to migrate and invade studied in 3D spheroid cultures. The importance of the effector pathways will be investigated through targeted gene inactivation and inhibitors. Finally,
MRCKa has two closely related family members, MRCKb and MRCKg, and also shares functional similarities with ROCK1 and ROCK2. With the aim to obtain a more efficient inhibition of cancer cell migration, the third objective seeks to investigate the overlapping functions of related kinases through combining knockouts of MRCKa in breast cancer cells with knockouts of MRCKb, MRCKg, ROCK1 and ROCK2.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology skin cancer
- medical and health sciences medical biotechnology genetic engineering gene therapy
- natural sciences biological sciences developmental biology
- medical and health sciences clinical medicine oncology breast cancer
- natural sciences biological sciences genetics genomes
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1165 KOBENHAVN
Denmark
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.